Trial Profile

Bortezomib (Velcade): A feasibility and phase II study in childhood relapsed acute lymphoblastic leukemia.

Status: Completed

Phase of Trial: Phase II

Latest Information Update: 22 Dec 2021

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Bortezomib (Primary) ; Dexamethasone; Methotrexate; Vincristine
Indications Precursor cell lymphoblastic leukaemia-lymphoma
Focus Therapeutic Use

Most Recent Events

30 Dec 2015 Status changed from recruiting to completed, according to Netherlands Trial Register.
10 Dec 2013 Interim pharmacokinetic results presented at the 55th Annual Meeting and Exposition of the American Society of Hematology.
29 Mar 2012 Actual initiation date (11 Jan 2010) added as reported by European Clinical Trials Database.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com